• SPX
  • 5969.34
  • 0.35 %
  • 20.6299
  • DJI
  • 44296.51
  • 0.97 %
  • 426.1602
  • N225
  • 38780.14
  • 1.3 %
  • 496.2891
  • FTSE
  • 8275.06
  • 0.16 %
  • 12.98
  • IXIC
  • 19003.65
  • 0.16 %
  • 31.2305
Lucid Diagnostics Inc. (LUCD) Stock Price, News & Analysis

Lucid Diagnostics Inc. (LUCD) Stock Price, News & Analysis

Currency in USD Disclaimer

$1.00

-$0

(0.1%)

Day's range
$0.96
Day's range
$1.02
50-day range
$0.73
Day's range
$1.12
  • Country: US
  • ISIN: US54948X1090
52 wk range
$0.63
Day's range
$1.58


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 1.97
  • Piotroski Score 4.00
  • Grade Buy
  • Symbol (LUCD)
  • Company Lucid Diagnostics Inc.
  • Price $1.00
  • Changes Percentage (0.1%)
  • Change -$0
  • Day Low $0.96
  • Day High $1.02
  • Year High $1.58

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/24/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $2.50
  • High Stock Price Target $3.00
  • Low Stock Price Target $2.50
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.26
  • Trailing P/E Ratio -0.61
  • Forward P/E Ratio -0.61
  • P/E Growth -0.61
  • Net Income $-52,666,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Lucid Diagnostics Inc. Frequently Asked Questions

  • What were the earnings of LUCD in the last quarter?

    In the last quarter Lucid Diagnostics Inc. earnings were on Monday, August, 12th. The Lucid Diagnostics Inc. maker reported -$0.20 EPS for the quarter, beating analysts' consensus estimates of -$0.22 by $0.02.

  • What is the Lucid Diagnostics Inc. stock price today?

    Today's price of Lucid Diagnostics Inc. is $1.00 — it has decreased by 0.1% in the past 24 hours. Watch Lucid Diagnostics Inc. stock price performance more closely on the chart.

  • Does Lucid Diagnostics Inc. release reports?

    Yes, you can track Lucid Diagnostics Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Lucid Diagnostics Inc. stock forecast?

    Watch the Lucid Diagnostics Inc. chart and read a more detailed Lucid Diagnostics Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Lucid Diagnostics Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Lucid Diagnostics Inc. stock ticker.

  • How to buy Lucid Diagnostics Inc. stocks?

    Like other stocks, LUCD shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Lucid Diagnostics Inc.'s EBITDA?

    Lucid Diagnostics Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Lucid Diagnostics Inc.’s financial statements.

  • What is the Lucid Diagnostics Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -21.6911037891, which equates to approximately -2,169.11%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Lucid Diagnostics Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Lucid Diagnostics Inc.'s financials relevant news, and technical analysis. Lucid Diagnostics Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Lucid Diagnostics Inc. stock currently indicates a “sell” signal. For more insights, review Lucid Diagnostics Inc.’s technical analysis.

  • A revenue figure for Lucid Diagnostics Inc. for its last quarter?

    Lucid Diagnostics Inc. published it's last quarterly revenues at $1.17 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.